Let our stock updates help direct you

Article Excerpt

DANAHER CORP. $325 is a buy. The company (New York symbol DHR; Manufacturing sector; Shares outstanding: 713.9 million; Market cap: $232.0 billion; Dividend yield: 0.3%; Takeover Target Rating: Medium; www.danaher.com) is a leading maker of precision-testing equipment and tools. Its customers include medical research labs and municipal water utilities. Danaher has now completed its acquisition of Aldevron LLC for $9.6 billion in cash. Founded in 1998 in Fargo, North Dakota, Aldevron specializes in making biologics for the pharmaceutical and biotechnology industry. Its products include plasmid DNA, mRNA and recombinant proteins used in vaccines, gene and cell therapy, gene editing and diagnostic applications. Meantime, in the three months ended July 2, 2021, Danaher’s revenue increased 36.3%, to $7.22 billion from $5.30 billion a year earlier. If you exclude the $20.7 billion acquisition of lab equipment maker Cytiva on March 31, 2020, sales during the quarter increased by 31.5%. Excluding one-time items, per-share earnings shot up 70.8%, to $2.46 from $1.44. Danaher is a buy. CARS.COM…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.